Despite delays in dosing of patients at its Toronto clinic and building its network of clinics in the U.S. because of COVID-19, closely-held Field Trip Psychedelics is finding opportunities to expand its psychedelic-enhanced treatments to improve mental wellness.
I am talking to Ronan Levy from "Field Trip Health" based in Canada. The company is providing clinics for evidence based legal psychedelic therapies to treat depression. But what I like about "Field Trip Health" is their attitude towards a really dated idea to call some people “sick” or “crazy”. Field Trip Health says, we treat people, not patients. “We are all sick and healthy at the same time. It’s just that some people need more support.” says Ronan.We discuss the design places for a psychedelic treatment should have. Should they look more like a spa? Or a clinic? Or do we need new designs? And do the “ well" need psychedelics to get “better"? Or should we only focus on clinically depressed people? But then again, these concepts and terms don’t work any more. Join me and Ronan talking new psychedelic solutions and why mindfullness is not enough anymore.
In the first of a series of interviews with the trailblazers of the psychedelics industry, Psilocybin Alpha spoke to Ronan Levy: Founder & Executive Chairman of Field Trip Health, Inc.
Company also announces appointment of Nathan Bryson as Chief Science Officer and Pharmaceutical Company Executives Dieter Weinand and Helen Boudreau to the Board of Directors Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the world’s first mental wellness company focused exclusively on psychedelics and psychedelic-enhanced psychotherapy, today announced the creation of Field Trip Discovery, the company’s newly formed drug development division.
The aptly named Field Trip Health clinic in Toronto is attempting to change the mental health narrative by providing clients with a ketamine-based therapy to treat depression and anxiety.
Field Trip, a company devoted to alternative psychedelic therapies, opened its first ketamine clinic in Toronto. Up next: Los Angeles and New York City. Special K isn’t just a party drug for ravers anymore.
Welcome to the first edition of Psyched, a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. MindMed Became the First Psychedelics Company to List Publicly on NEO Stock Exchange, Created New Committee
Field Trip Health Inc., a wholly owned subsidiary of Field Trip Psychedelics Inc., (“Field Trip” or the “Company“), the world’s first mental wellness company focused on psychedelics and psychedelic-enhanced psychotherapy, today announced the opening of its first medical centre, in Toronto, dedicated exclusively to the administration of psychedelic-enhanced psychotherapy.
Field Trip Health, a wholly owned subsidiary of Field Trip Psychedelics, a mental wellness company focused on psychedelics and psychedelic-enhanced psychotherapy, debuted its first medical center in Toronto on Wednesday. The center will be dedicated exclusively to the administration of psychedelic-enhanced psychotherapy.
Field Trip Health Inc., a wholly owned subsidiary of Field Trip Psychedelics Inc., (“Field Trip” or the “Company“), the world’s first mental wellness company focused on psychedelics and psychedelic-enhanced psychotherapy, today announced the opening of its first medical centre, in Toronto, dedicated exclusively to the administration of psychedelic-enhanced psychotherapy. The centre seeks to enhance the lives of patients seeking mental health treatment through psychedelics and psychedelic-enhanced psychotherapy.
Field Trip Psychedelics Inc, the world’s first mental wellness company focused exclusively on psychedelics and psychedelic-enhanced psychotherapy, is pleased to announce the closing of its oversubscribed Series A financing round. The financing, which was completed through a private placement, raised $8.5M USD for the Company.
In 1967, Jimi Hendrix’s “Are You Experienced?” became the anthem for a generation of psychedelic initiates. Over fifty years later, at the recent Economics of Psychedelic Investing conference, the cultural touchstone was Michael Pollan’s NYT bestseller, ”How to Change Your Mind.” And as Lewis Goldberg, Principal of KCSA Strategic Communications, noted to the 200-plus attendants, it should have already been required reading for everyone in the room.
Among many esteemed guests, Ronan Levy talks the future of psychedelics and the impact potential that the space has on healthcare. Listen at the link, starting at 1:16:00.
Ronan Levy, with his company Field Trip Ventures, are building the infrastructure for legal psychedelic therapy.
Could Chicago’s political history derail progress in the psychedelic sector?
It may only be a matter of time before entrepreneurs realize the potential of psychedelics and start to look for investors
Ronan Levy never used or experimented with drugs or alcohol while growing up. He even admits to being skeptical of the therapeutic applications for cannabis as he was getting into the industry in 2013. But Levy was open minded and felt that criminalizing consumption and production of cannabis (and other illicit substances that have low harm profiles) made little political or regulatory sense. He was excited to support the burgeoning cannabis industry and as the evidence for medical cannabis continued to build, Levy directly witnessed the profoundly positive impact his clinics were having on patients’ lives. His cautious optimism morphed into avid support for cannabis as medicine.
“Psychedelics are the next big thing,” Ronan Levy, co-founder of Field Trip Psychedelics, an integrated company in legal psychedelics and psychedelic-assisted psychotherapy, told me during a lunch in New York City a few months ago. He looked perfectly sane, wearing a suit, and articulating properly. He was definitely not tripping.
“If cannabis has been significant, psilocybin will have much more of a therapeutic impact,” said Toronto-based cannabis-turned-psychedelics entrepreneur Ronan Levy, when Green Market Report caught up with him to talk about the future of research on psychedelics.
Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the world’s first integrated company in legal psychedelics and psychedelic-assisted psychotherapy, is pleased to announce the appointment of Dr. Michael Ehlers as a Strategic Advisor to the Company.
Ronan Levy, founder of Field Trip Ventures, joins CNBC’s “Power Lunch” to discuss the widening research into psychedelic drugs and how they can be used to help patients in therapy.
Money is going into medical use of mind-altering drugs.
Some of the country’s top psychiatric researchers are exploring whether hallucinogens, when taken in a controlled and clinical environment, can help people suffering from severe depression.
The world’s first magic mushroom research centre is launching this year in Jamaica. The centre will be located at the University of the West Indies in Mona, and funded by Canadian psychedelic company, Field Trip.
Let’s dive right in. The spate of vape-related illnesses continues, with Missouri announcing the eighth death in the US on Thursday. The FDA is also launching a criminal probe into the matter, alongside the CDC’s investigation. We’re keeping you up to date on those developments here.
Denver and Oakland have decriminalized magic mushrooms, but campaigners here want to go even further.
Field Trip Ventures is tackling Canada’s ‘broken’ mental healthcare system by building the world’s first legal research centre to study magic mushrooms
Field Trip Ventures Inc., a Toronto-based firm aimed at using psychedelics to treat mental illness, is planning to build the world’s first legal research and cultivation facility for psilocybin-producing mushrooms.
What exactly makes magic mushrooms psychedelic? How psychedelic are they? Are there any undiscovered psychedelic molecules hidden inside those freaky fungi? These questions will be the focus of the world’s first research center focused on these psychedelic lifeforms, launching this year in the University of the West Indies in Mona, Jamaica. The research is wholly funded by a Canadian psychedelic company, Field Trip Ventures, which plans to put the findings to profitable use.
A few entrepreneurs and investors see opportunity for novel mental-health treatments, but traditional health-care investors say it is too early Psychedelic substances are gaining legitimacy as a treatment for mental illnesses, prompting a handful of entrepreneurs and venture-capital investors to look for business opportunities in the nascent sector.
DENVER – Tucker Max tried to drown his childhood sadness in booze and sex. That didn’t work, although it netted him a best-selling book and a movie based on his story. As he got older, he tried working out, and got fit but still felt lousy. He also tried business, co-founding publishing house Scribe Media, but his mind still struggled.
Ronan Levy, Founder of Field Trip Ventures sits down with The Green Rush this week as the team looks to cover something a little different: psychedelics. Field Trip Ventures is a first-of-its-kind venture that is blending operational execution with strategic investing across all aspects of the psychedelics supply chain.
The first states in the United States are working to legalize magic mushrooms. The movement is in its nascent stages, but following the path of the cannabis in the US, different models of decriminalization are already emerging.
Oregon is one step closer to voting in November 2020 to legalize medicinal psilocybin mushrooms for adults in the state. While current laws prohibit the use and possession of psilocybin, a hallucinogenic compound from “magic mushrooms,” activists in the state are championing the Oregon Psilocybin Services Act.
Field Trip Ventures wants drugs like LSD, psilocybin, and MDMA to become the “new wave of the path that’s been created by cannabis.
With cannabis now legal in Canada, a new drug — Psilocybe cubensis (‘magic mushroom or ‘shrooms’) — has started to grow on those with depression and addictions. Psilocybe is a hallucinogen found in 100 species of mushrooms. They are illegal to posses in Canada with a sentence up to six months in jail or $1,000 fine or both.
Good day. Big-time venture capital is pouring into Latin America.
Every week we track the business, tech and investment trends in CPG, retail, restaurants, agriculture, cooking and health, so you don’t have to. Here are some of this week’s top headlines.
As the legalization of medical cannabis has swept the globe, it’s also paved the way for another new health frontier: psychedelic medicine.
As cannabis legalization spreads across the globe, another mind-altering drug is trying to follow in its tracks: magic mushrooms.
The team behind the medical clinics that were eventually sold to Aurora Cannabis is now attempting to build a healthcare infrastructure based on research into psychedelics as treatments for depression and PTSD. Field Trip Ventures president Mujeeb Jafferi explains.
There’s no doubt about it—a classical psychedelic experience has the capacity to plant a seed in each of us that lets us behold, envision, and temporarily inhabit a world in which we are all connected in love, harmony, and mutual support. What we do with this vision after the experience ends, and how to integrate it into our lives and into the messy, imperfect, and unjust world around us is the tricky part.
get in touch
Are you disappointed with the results from other therapies or medications? Is something blocking progress, but you’re not sure what? Find out if psychedelic-enhanced psychotherapy is right for you.